Related Experiment Video

Updated: May 20, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.4K

Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling

Mahyar Haki1, Reihaneh Bayat2

  • 1Biomedical Engineering Department, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran.

International Journal of Molecular and Cellular Medicine
|March 24, 2025
PubMed

Insights

This study reviews targeted therapies for breast cancer subtypes, including hormone receptor-positive and triple-negative. It highlights emerging treatments and challenges like therapeutic resistance, offering insights into novel drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer presents diverse subtypes: hormone receptor-positive (ER+), HER2-positive, and triple-negative (TNBC).
  • Current targeted therapies focus on estrogen receptors (ER) and HER2, but face challenges with inherent or acquired resistance.
  • Understanding tumor biology has identified new targets in pathways like PI3K/mTOR, cell-cycle regulation, heat shock protein, and epigenetics.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging targeted therapies for distinct breast cancer subtypes.
  • To discuss the efficacy and limitations of targeted treatments across ER+, HER2+, and TNBC.
  • To highlight novel therapeutic strategies and targets being explored in breast cancer research.

Main Methods:

  • Literature review of targeted therapies for breast cancer.
  • Analysis of clinical trial outcomes for novel therapeutic agents.
  • Categorization of therapies based on breast cancer subtypes (ER+, HER2+, TNBC).

Main Results:

  • Everolimus (mTOR inhibitor) is approved for advanced ER+ breast cancer resistant to aromatase inhibitors.
  • Emerging targeted therapies show promise in clinical experiments for various pathways.
  • Established targeted therapies for TNBC are limited, with uncertain efficacy of PARP inhibitors in non-BRCA mutated TNBC.

Conclusions:

  • Targeted therapies are crucial for managing breast cancer subtypes, with ongoing advancements.
  • Addressing therapeutic resistance and identifying new targets are key priorities in breast cancer treatment.
  • Further research is needed to develop effective targeted strategies, especially for triple-negative breast cancer.
Keywords:
BreastCancerPathwaysTarget

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.6K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K